PT808898E - Reagente e metodo para inibicao da expressao de n-ras - Google Patents

Reagente e metodo para inibicao da expressao de n-ras

Info

Publication number
PT808898E
PT808898E PT97107706T PT97107706T PT808898E PT 808898 E PT808898 E PT 808898E PT 97107706 T PT97107706 T PT 97107706T PT 97107706 T PT97107706 T PT 97107706T PT 808898 E PT808898 E PT 808898E
Authority
PT
Portugal
Prior art keywords
molecules
inhibiting
reagent
ras expression
pharmaceuticals
Prior art date
Application number
PT97107706T
Other languages
English (en)
Inventor
Eugen Uhlmann
Joachim Engels
Michaela Scherr
Arnold Ganser
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PT808898E publication Critical patent/PT808898E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
PT97107706T 1996-05-24 1997-05-12 Reagente e metodo para inibicao da expressao de n-ras PT808898E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96108326 1996-05-24

Publications (1)

Publication Number Publication Date
PT808898E true PT808898E (pt) 2004-10-29

Family

ID=8222818

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97107706T PT808898E (pt) 1996-05-24 1997-05-12 Reagente e metodo para inibicao da expressao de n-ras

Country Status (9)

Country Link
US (1) US6037463A (pt)
EP (1) EP0808898B1 (pt)
JP (1) JPH1052264A (pt)
AT (1) ATE267247T1 (pt)
CA (1) CA2205075C (pt)
DE (1) DE69729145T2 (pt)
DK (1) DK0808898T3 (pt)
ES (1) ES2221942T3 (pt)
PT (1) PT808898E (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US7812149B2 (en) * 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040171030A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
FR2812945B1 (fr) * 2000-08-10 2002-10-04 Aventis Pharma Sa Utilisation de la proteine grf1 et cellules exprimant la proteine grf1 pour le criblage de molecules
WO2003064621A2 (en) * 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP3415625A1 (en) 2002-02-01 2018-12-19 Life Technologies Corporation Double-stranded oligonucleotides
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
US8604183B2 (en) * 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US20060241072A1 (en) * 2003-06-20 2006-10-26 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
US8569474B2 (en) * 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP1765416A4 (en) * 2004-06-03 2010-03-24 Isis Pharmaceuticals Inc DOUBLE-STRANDED COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENETIC MODULATION
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) * 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
EP2207570A2 (en) 2007-09-14 2010-07-21 Nitto Denko Corporation Drug carriers
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871838A (en) * 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
WO1991018913A1 (en) * 1990-06-07 1991-12-12 City Of Hope Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
AU7152191A (en) * 1990-06-07 1991-12-31 City Of Hope Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
PL169576B1 (pl) * 1990-10-12 1996-08-30 Max Planck Gesellschaft Sposób wytwarzania czasteczki RNA o aktywnosci katalitycznej PL PL
KR930016437A (ko) * 1992-01-22 1993-08-26 귀틀라인, 슈미트 올리고뉴클레오티드 유사체, 이의 제조방법 및 용도
AU687001B2 (en) * 1992-05-14 1998-02-19 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting cancer development
EP0593901B2 (de) * 1992-09-24 2008-04-09 Sanofi-Aventis Deutschland GmbH Oligoribonucleotid- und Ribozym-Analoga mit terminalen 3'-3'-bzw.5'-5'-Verknüpfungen
DE4408528A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung

Also Published As

Publication number Publication date
US6037463A (en) 2000-03-14
CA2205075C (en) 2011-08-09
EP0808898A1 (en) 1997-11-26
CA2205075A1 (en) 1997-11-24
DE69729145T2 (de) 2005-06-09
EP0808898B1 (en) 2004-05-19
DE69729145D1 (de) 2004-06-24
JPH1052264A (ja) 1998-02-24
ES2221942T3 (es) 2005-01-16
ATE267247T1 (de) 2004-06-15
DK0808898T3 (da) 2004-09-27

Similar Documents

Publication Publication Date Title
PT808898E (pt) Reagente e metodo para inibicao da expressao de n-ras
BR9908280A (pt) Inibidores de enzimas de fosfolipase
DE69528470D1 (de) Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel
AU3142597A (en) Dha-pharmaceutical agent conjugates
IL109780A0 (en) Saccharin derivative proteolytic enzyme inhibitors, their preparation and pharmaceutical compositions containing them
BR0312421A (pt) Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos
PL332078A1 (en) Highly selective inhibitors of butyrylcholinesterase for trating and diagnosing the alzheimer disease and dementia
BRPI0015533B8 (pt) enzima alfa-l-iduronidase humana recombinante, composição farmacêutica compreendendo a mesma e método para sua purificação
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
TW225532B (pt)
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
WO1998032846A3 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos
AU3530999A (en) Monomer protein with bone morphogenetic activity and medicinal agent containing the same for preventing and treating diseases of cartilage and bone
NO924309D0 (no) Sammensetninger og fremgangsmaater for modulering av rna-aktiviteter gjennom modifikasjon av 5' cap-strukturen til rna
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
AU8243198A (en) Remedies for solid tumor containing wilms' tumor gene (wt1) expression inhibitors
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
BR9814188A (pt) "agonistas de 5-ht1f"
BR9810481A (pt) Processo para preparação de 1h-indol-3-glioxamidas 4-substituìdas.
DK0808306T3 (da) Hidtil ukendte pyridin- eller pyridazinderivater, fremgangsmåder til fremstilling deraf og lægemidler indeholdende disse fo
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
FR2770127B1 (fr) Procede de marquage des instruments de chirurgie
BR9811875A (pt) Composição e processo de tratamento de câncer com ácido tânico e complexos de tanino
BR9712711A (pt) Sìntese de benzo[f]quinolinonas